CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication

Table 1 Univariable analysis of the clinical factors and genotyped polymorphisms n (%)

Variable	Eradication (n = 79)	No eradication (n = 6)	P value
Age (yr)	51.95 ± 13.48	53.17 ± 12.06	0.831
Sex (male:female)	35:44	2:4	0.693
Smoking	14 (17.72)	0 (0)	0.583
Alcohol	19 (24.05)	1 (16.67)	1.000
Betel	1 (1.27)	0 (0)	1.000
Coffee	56 (70.89)	4 (66.67)	1.000
Tea	59 (74.68)	4 (66.67)	0.646
NSAID user	7 (8.86)	1 (16.67)	0.458
Steroid user	3 (3.80)	0 (0)	1.000
Anticoagulant user	4 (5.06)	1 (16.67)	0.316
CYP2C19 genotype			0.380
HomoEM	33 (41.77)	4 (66.67)
HeteroEM	36 (45.57)	1 (16.67)
PM	10 (12.66)	1 (16.67)
IL-1β-511 genotype			0.934
CC	25 (31.65)	2 (33.33)
CT	32 (40.51)	2 (33.33)
TT	22 (27.85)	2 (33.33)
Resistance (n = 65)	(n = 61)	(n = 4)
Amoxicillin	0/61 (0)	0/4 (0)
Clarithromycin	8/61 (13.11)	0/4 (0)	1.000
Metronidazole	25/61 (40.98)	1/4 (25.00)	0.644

Data are expressed as mean ± SD or n (%). NSAID: Non-steroid anti-inflammatory drug; CYP2C19: Cytochrome P450 2C19; EM: Extensive metabolizer; PM: Poor metabolizer; IL-1β: Interleukin-1β.